The immunogenicity risk of a therapeutic protein or monoclonal antibody can be assessed by SciCross in silico tools. Putative T-cell epitopes are identified and both individual peptides or longer regions with high immunogenicity risk can be identified. This is valuable approach when several drug candidates are being evaluated at an early stage – if no difference in efficacy, move on with the least immunogenic one! The results can also be used to target certain regions in de-immunization attempts. In addition, population specific aspects can be considered by looking at specific alleles or allele combinations.